<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-23233" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Hypertonic Fluids</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Mason</surname>
            <given-names>Alexi</given-names>
          </name>
          <aff>Michigan State University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Malik</surname>
            <given-names>Ahmad</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ginglen</surname>
            <given-names>Jacob G.</given-names>
          </name>
          <aff>McLaren Oakland Hospital</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Alexi Mason declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ahmad Malik declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jacob Ginglen declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>17</day>
          <month>4</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-23233.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Clinicians use hypertonic fluids to increase intravascular fluid volume. Hypertonic saline can be utilized in the treatment of hyponatremia. Hypertonic saline and mannitol are both indicated to reduce intracranial pressure. This activity will highlight the mechanism of action, adverse events, and contraindications of hypertonic fluids in the management of hyponatremia and increased intracranial pressure.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the mechanisms of action of hypertonic saline and mannitol.</p></list-item><list-item><p>Review the adverse effects and contraindications of hypertonic saline and mannitol.</p></list-item><list-item><p>Outline the route of administration and appropriate dosing for hypertonic fluids.</p></list-item><list-item><p>Explain the importance of improving care coordination among the interprofessional team to improve care for patients with increased intracranial pressure and hypertonic fluids in patient management.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23233&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23233">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-23233.s2" sec-type="Indications">
        <title>Indications</title>
        <p>
<bold>Hypertonic Saline</bold>
</p>
        <p>Hypertonic saline is a crystalloid intravenous fluid composed of NaCl dissolved in water with a higher sodium concentration than normal blood serum. Both 3% and 5% hypertonic saline (HS) is currently FDA-approved for use in hyponatremia and increased intracranial pressure (ICP). Patients with hyponatremia with severe features should have their serum sodium gradually corrected with boluses of hypertonic saline. Patients should have their serum sodium monitored at regular intervals and can receive multiple boluses a day.<xref ref-type="bibr" rid="article-23233.r1">[1]</xref></p>
        <p>Hypertonic saline should be discontinued once the patient&#x02019;s symptoms improve or they have an adequate increase in serum sodium. Cerebral edema and elevated intracranial pressure (ICP) are significant causes of morbidity and mortality in patients with intracranial tumors, cerebral hematomas, traumatic brain injuries, cerebral infarcts, and intracranial hemorrhages. Hypertonic saline increases the osmolarity of the blood, which allows fluid from the extravascular space to enter the intravascular space, which leads to decreases in brain edema, improved cerebral blood flow, and decreased CSF production. Research shows that 3% hypertonic saline decreases ICP similarly to 20% mannitol.<xref ref-type="bibr" rid="article-23233.r2">[2]</xref> Both hypertonic fluids have similar effects on hemodynamics. Hypertonic saline leads to increases in serum sodium and has less of a diuretic effect than mannitol, likely due to the increased serum sodium causing ADH release. Hypertonic saline administered after mannitol in traumatic brain injury has also demonstrated improvement of cerebral oxygenation in addition to lowering ICP.<xref ref-type="bibr" rid="article-23233.r3">[3]</xref></p>
        <p>Due to there being no guidelines regarding the administration of hypertonic saline for increased ICP, various studies have used concentrations of 3% to 23.5% NaCl.<xref ref-type="bibr" rid="article-23233.r4">[4]</xref></p>
        <p>
<bold>Mannitol</bold>
</p>
        <p>Mannitol is a crystalloid intravenous fluid composed of a six-carbon simple sugar dissolved in water. It is FDA-approved for use in decreasing intracranial pressure and brain mass and decreasing intraocular pressure when other interventions have failed to do so. When needed, 15 to 25% mannitol can be given as a bolus to reduce intracranial pressure and intraocular pressure. Mannitol is solely confined to the intravascular space when administered intravenously, unlike hypertonic saline, which can have some movement of electrolytes into the interstitial&#x000a0;space.</p>
      </sec>
      <sec id="article-23233.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Hypertonic fluids contain a higher concentration of solute compared to plasma and interstitial fluid; this creates an osmotic gradient and drives fluid from the interstitial space into the intravascular space. This increase in intravascular volume increases mean arterial pressure (MAP), stroke volume (SV), and cardiac output (CO) when compared with equal volumes of normal saline or other isotonic fluids.<xref ref-type="bibr" rid="article-23233.r5">[5]</xref> There is also a significant increase in end-diastolic pressure and a subsequent decrease in pulmonary vascular resistance. Hypertonic saline requires less overall volume administered to achieve similar plasma volumes as larger volumes of normal saline.<xref ref-type="bibr" rid="article-23233.r6">[6]</xref> Hypertonic saline stimulates vasopressin release from the pituitary gland, which decreases water loss through the kidneys.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="30829667">[7]</ext-link>&#x000a0;In comparison, when given intravenously, mannitol is only minimally metabolized by the body and is rapidly excreted by the kidney. Less than 10% of mannitol is reabsorbed, increasing the osmolarity of the glomerular filtrate and inducing diuresis.</p>
      </sec>
      <sec id="article-23233.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Hypertonic fluids are administered parenterally via intravenous infusion. Infusion volumes and rates depend on clinical indication.</p>
        <p>
<bold>Hypertonic Saline</bold>
</p>
        <p>In patients with severe hyponatremia, serum sodium should undergo correction by 4 to 6 mEq/L per day, which can be achieved with 100 mL boluses of 3% HS at 10-minute intervals up to three total boluses. Some authorities recommend up to&#x000a0; 8 mEq/L per day.<xref ref-type="bibr" rid="article-23233.r7">[8]</xref> Less severe hyponatremia can achieve control with enough hypertonic saline to manage symptoms.<xref ref-type="bibr" rid="article-23233.r8">[9]</xref> Due to the insufficient number of patients over age 65 in various trials, hypertonic fluids should start at the lowest ends of the dosing scale in the geriatric population. Pediatric traumatic brain injury generally receives treatment with a 6.5 to 10 mL/kg bolus of hypertonic saline.<xref ref-type="bibr" rid="article-23233.r9">[10]</xref> Administration via a peripheral intravenous catheter is acceptable if no other access is available, but central venous access is the preferred route.&#x000a0;</p>
        <p>
<bold>Mannitol</bold>
</p>
        <p>Mannitol boluses should be given as 0.25 to 2 g/kg body weight of 15 to 25% mannitol over 30 minutes to 1 hour for the treatment of increased intracranial or intraocular pressures. Pediatric patients should receive a similar 1 to 2g/kg body weight bolus over the same timeframe. Peripheral intravenous catheters are acceptable routes of administration.</p>
      </sec>
      <sec id="article-23233.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>
<bold>Hypertonic Saline</bold>
</p>
        <p>There are few adverse effects associated with hypertonic saline, though most are associated with longer infusion periods, as opposed to boluses. One possible side effect is hyperchloremic metabolic acidosis due to the addition of NaCl. Patients may also develop hypernatremia with long-term administration for the same reasons. One other known effect is osmotic demyelination syndrome, when severe hyponatremia is corrected too rapidly. Hypertonic saline is also pregnancy category C and is only used if necessary. The most common adverse effects are related to the route of administration and include infection at the IV site, thrombophlebitis, extravasation, and hypervolemia.</p>
        <p>
<bold>Mannitol</bold>
</p>
        <p>Common adverse reactions after mannitol administration are pulmonary congestion, electrolyte abnormalities, acidosis, marked diuresis, dehydration, headache, and injection site reactions, among others. There have been no animal reproduction studies performed with mannitol, so it is unknown whether it would harm a human fetus. Mannitol should only be used in pregnant women if necessary.</p>
      </sec>
      <sec id="article-23233.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>
<bold>Hypertonic Saline</bold>
</p>
        <p>There are no known specific contraindications for hypertonic saline, according to the FDA. However, caution is necessary with hypertonic saline in patients with congestive heart failure or renal insufficiency due to their already increased fluid and sodium loads.</p>
        <p>
<bold>Mannitol</bold>
</p>
        <p>Mannitol has several contraindications, including:</p>
        <list list-type="bullet">
          <list-item>
            <p>Established anuria due to severe renal disease</p>
          </list-item>
          <list-item>
            <p>Pulmonary congestion and frank pulmonary edema</p>
          </list-item>
          <list-item>
            <p>Active internal bleeding</p>
          </list-item>
          <list-item>
            <p>Severe dehydration</p>
          </list-item>
          <list-item>
            <p>Hypersensitivity to mannitol</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23233.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Fluid and electrolytes require monitoring with the administration of all hypertonic fluids, with particular attention paid to serum sodium, potassium, and fluid ins/outs. Evaluation of circulatory and renal function is necessary before administering mannitol and evaluated during treatment. When treating increased ICP with mannitol, a CSF pressure measurement should take place within fifteen minutes after administration.</p>
      </sec>
      <sec id="article-23233.s8" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>An interprofessional team approach, comprised of clinicians, nurses, and pharmacists, is most appropriate when administering hypertonic fluids &#x02014; extra care is necessary to monitor circulatory and renal function as well as serum electrolyte concentrations. Fluid ins and outs must be carefully monitored by nursing staff, particularly with mannitol, reporting abnormalities right away. Hypertonic fluids should be stopped if significant abnormalities in electrolytes or fluid volumes develop. It is noteworthy that there is a lack of research regarding hypertonic fluids. More work remains to determine the value of hypertonic fluids not only in the management of critically ill patients but in the pre-hospital setting for cases of hypovolemia and shock.</p>
        <p>In summary, administration of hypertonic saline and/or mannitol requires an interprofessional team approach, including clinicians (MDs, DOs, NPs, PAs), specialists, specialty-trained nurses, and pharmacists, all collaborating across disciplines to achieve optimal patient results. [Level 5]</p>
      </sec>
      <sec id="article-23233.s9">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23233&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23233">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/23233/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=23233">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-23233.s10">
        <title>References</title>
        <ref id="article-23233.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Williams</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Gallagher</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Handley</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Stephens</surname>
                <given-names>JW</given-names>
              </name>
            </person-group>
            <article-title>The clinical management of hyponatraemia.</article-title>
            <source>Postgrad Med J</source>
            <year>2016</year>
            <month>Jul</month>
            <volume>92</volume>
            <issue>1089</issue>
            <fpage>407</fpage>
            <page-range>407-11</page-range>
            <pub-id pub-id-type="pmid">27044859</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23233.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sokhal</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Rath</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Chaturvedi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dash</surname>
                <given-names>HH</given-names>
              </name>
            </person-group>
            <article-title>Comparison of 20% mannitol and 3% hypertonic saline on intracranial pressure and systemic hemodynamics.</article-title>
            <source>J Clin Neurosci</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>42</volume>
            <fpage>148</fpage>
            <page-range>148-154</page-range>
            <pub-id pub-id-type="pmid">28342705</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23233.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oddo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Levine</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Frangos</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Carrera</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Maloney-Wilensky</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Pascual</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Kofke</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Mayer</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>LeRoux</surname>
                <given-names>PD</given-names>
              </name>
            </person-group>
            <article-title>Effect of mannitol and hypertonic saline on cerebral oxygenation in patients with severe traumatic brain injury and refractory intracranial hypertension.</article-title>
            <source>J Neurol Neurosurg Psychiatry</source>
            <year>2009</year>
            <month>Aug</month>
            <volume>80</volume>
            <issue>8</issue>
            <fpage>916</fpage>
            <page-range>916-20</page-range>
            <pub-id pub-id-type="pmid">19293171</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23233.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Witherspoon</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ashby</surname>
                <given-names>NE</given-names>
              </name>
            </person-group>
            <article-title>The Use of Mannitol and Hypertonic Saline Therapies in Patients with Elevated Intracranial Pressure: A Review of the Evidence.</article-title>
            <source>Nurs Clin North Am</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>52</volume>
            <issue>2</issue>
            <fpage>249</fpage>
            <page-range>249-260</page-range>
            <pub-id pub-id-type="pmid">28478873</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23233.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pfortmueller</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Schefold</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Hypertonic saline in critical illness - A systematic review.</article-title>
            <source>J Crit Care</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>42</volume>
            <fpage>168</fpage>
            <page-range>168-177</page-range>
            <pub-id pub-id-type="pmid">28746899</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23233.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Joseph</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Aziz</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Snell</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pandit</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Hays</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kulvatunyou</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>O'Keeffe</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wynne</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Friese</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Rhee</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>The physiological effects of hyperosmolar resuscitation: 5% vs 3% hypertonic saline.</article-title>
            <source>Am J Surg</source>
            <year>2014</year>
            <month>Nov</month>
            <volume>208</volume>
            <issue>5</issue>
            <fpage>697</fpage>
            <page-range>697-702</page-range>
            <pub-id pub-id-type="pmid">24928332</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23233.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Adrogu&#x000e9;</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Madias</surname>
                <given-names>NE</given-names>
              </name>
            </person-group>
            <article-title>Hyponatremia.</article-title>
            <source>N Engl J Med</source>
            <year>2000</year>
            <month>May</month>
            <day>25</day>
            <volume>342</volume>
            <issue>21</issue>
            <fpage>1581</fpage>
            <page-range>1581-9</page-range>
            <pub-id pub-id-type="pmid">10824078</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23233.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sterns</surname>
                <given-names>RH</given-names>
              </name>
            </person-group>
            <article-title>Disorders of plasma sodium--causes, consequences, and correction.</article-title>
            <source>N Engl J Med</source>
            <year>2015</year>
            <month>Jan</month>
            <day>01</day>
            <volume>372</volume>
            <issue>1</issue>
            <fpage>55</fpage>
            <page-range>55-65</page-range>
            <pub-id pub-id-type="pmid">25551526</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23233.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Niknam</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mistry</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lumba-Brown</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Pediatric hypertonic saline use in emergency departments.</article-title>
            <source>Am J Emerg Med</source>
            <year>2019</year>
            <month>May</month>
            <volume>37</volume>
            <issue>5</issue>
            <fpage>981</fpage>
            <page-range>981-983</page-range>
            <pub-id pub-id-type="pmid">30274762</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
